VBL Therapeutics Closes $8.1 Million Registered Direct Offering to Key Current Shareholders Priced At-the-Market under Nasdaq Rules
May 13, 2020 18:23 ET
|
VBL Therapeutics
TEL AVIV, Israel, May 13, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced offering of 5,142,857 ordinary shares of the Company,...
VBL Therapeutics Closes $10.0 Million Registered Direct Offering and Announces $8.1 Million Registered Direct Offering to Key Current Shareholders, Each Priced At-the-Market under Nasdaq Rules
May 12, 2020 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, May 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced registered direct offering of 6,349,208 ordinary...
VBL Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
May 07, 2020 09:22 ET
|
VBL Therapeutics
TEL AVIV, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has entered into definitive agreements with several institutional investors for the...
VBL Presents New Data on MOSPD2 Antibodies as Potential Treatment for NASH and Colitis at DDW
May 06, 2020 07:00 ET
|
VBL Therapeutics
Study was rated in the top 10% of all abstracts in this category and was selected as Poster of Distinction Data demonstrate the potential of VBL's proprietary MOSPD2 mAbs for chronic inflammatory...
VBL Therapeutics to Report First Quarter 2020 Financial Results on May 14
May 04, 2020 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, May 04, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL First-in-class MOSPD2 Antibodies Show Potential for Treatment for CNS Inflammation
May 04, 2020 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, May 04, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) is pleased to announce the publication of a new manuscript demonstrating the potential of MOSPD2 antibodies for...
VBL Therapeutics Awarded 3.2 Million NIS Non-Dilutive Grant by the Israel Innovation Authority for VB-111
April 21, 2020 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, April 21, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that it has been awarded a non-dilutive grant of up to 3.175 million New Israeli Shekels (NIS)...
VBL Therapeutics Announces New Milestone Event in the VB-201 Collaboration for Veterinary Use
April 06, 2020 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, April 06, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), announced today that it has reached a milestone event under its collaborative agreement with a world-leading...
Following Positive Interim Analysis, VB-111 Global Study in Ovarian Cancer to Extend to Japan via Collaboration with NanoCarrier
April 02, 2020 09:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, April 02, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that following the positive interim analysis in the OVAL study, its Japanese licensee...
VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study
March 26, 2020 07:57 ET
|
VBL Therapeutics
OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion, of an absolute percentage advantage of 10%...